TScan Therapeutics (TCRX) Osake Kurssi

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 145 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The firm is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The firm has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The company is also advancing six solid tumor programs: TSC-204, entering Phase I development; TSC-200 and TSC-203, in IND-enabling activities; TSC-201, in lead optimization, and TSC-202 and TSC-205, in discovery.